BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12569288)

  • 1. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen, or vindesine plus tamoxifen: a prospective randomized study.
    Cocconi G; Passalacqua R; Foladore S; Carlini P; Acito L; Maiello E; Marchi M; Gebbia V; Di Sarra S; Beretta M; Bacchi M
    Melanoma Res; 2003 Feb; 13(1):73-9. PubMed ID: 12569288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma).
    Sertoli MR; Queirolo P; Bajetta E; Del Vecchio M; Comella G; Barduagni L; Bernengo MG; Vecchio S; Criscuolo D; Bufalino R; Morabito A; Cascinelli N
    Melanoma Res; 1999 Oct; 9(5):503-9. PubMed ID: 10596917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study.
    Ringborg U; Rudenstam CM; Hansson J; Hafström L; Stenstam B; Strander H
    Med Oncol Tumor Pharmacother; 1989; 6(4):285-9. PubMed ID: 2693850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
    Rusthoven JJ; Quirt IC; Iscoe NA; McCulloch PB; James KW; Lohmann RC; Jensen J; Burdette-Radoux S; Bodurtha AJ; Silver HK; Verma S; Armitage GR; Zee B; Bennett K
    J Clin Oncol; 1996 Jul; 14(7):2083-90. PubMed ID: 8683240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen.
    Cocconi G; Bella M; Calabresi F; Tonato M; Canaletti R; Boni C; Buzzi F; Ceci G; Corgna E; Costa P
    N Engl J Med; 1992 Aug; 327(8):516-23. PubMed ID: 1635566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma.
    Agarwala SS; Ferri W; Gooding W; Kirkwood JM
    Cancer; 1999 May; 85(9):1979-84. PubMed ID: 10223239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial.
    Jungnelius U; Ringborg U; Aamdal S; Mattsson J; Stierner U; Ingvar C; Malmström P; Andersson R; Karlsson M; Willman K; Wist E; Bjelkengren G; Westberg R
    Eur J Cancer; 1998 Aug; 34(9):1368-74. PubMed ID: 9849419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
    Pectasides D; Yianniotis H; Alevizakos N; Bafaloukos D; Barbounis V; Varthalitis J; Dimitriadis M; Athanassiou A
    Br J Cancer; 1989 Oct; 60(4):627-9. PubMed ID: 2803936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
    Chapman PB; Einhorn LH; Meyers ML; Saxman S; Destro AN; Panageas KS; Begg CB; Agarwala SS; Schuchter LM; Ernstoff MS; Houghton AN; Kirkwood JM
    J Clin Oncol; 1999 Sep; 17(9):2745-51. PubMed ID: 10561349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study.
    Jelić S; Babovic N; Kovcin V; Milicevic N; Milanovic N; Popov I; Radosavljevic D
    Melanoma Res; 2002 Feb; 12(1):91-8. PubMed ID: 11828263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.
    Falkson CI; Ibrahim J; Kirkwood JM; Coates AS; Atkins MB; Blum RH
    J Clin Oncol; 1998 May; 16(5):1743-51. PubMed ID: 9586887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma.
    Creagan ET; Suman VJ; Dalton RJ; Pitot HC; Long HJ; Veeder MH; Vukov AM; Rowland KM; Krook JE; Michalak JC
    J Clin Oncol; 1999 Jun; 17(6):1884-90. PubMed ID: 10561229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
    Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
    Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy with dacarbazine and vindesine in the treatment of metastatic malignant melanoma.
    Vorobiof DA; Sarli R; Falkson G
    Cancer Treat Rep; 1986 Jul; 70(7):927-8. PubMed ID: 3719588
    [No Abstract]   [Full Text] [Related]  

  • 15. Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients.
    Rixe O; Borel C; Paraiso D; Benhammouda A; Petit T; Antoine E; Bizzari JP; Auclerc G; Soubrane C; Weil M
    Melanoma Res; 1995 Dec; 5(6):419-24. PubMed ID: 8589616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
    Saba HI; Cruse CW; Wells KE; Klein CJ; Reintgen DS
    Ann Plast Surg; 1992 Jan; 28(1):60-4. PubMed ID: 1642408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
    Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
    Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A phase I-II trial.
    Ringborg U; Jungnelius U; Hansson J; Strander H
    Am J Clin Oncol; 1990 Jun; 13(3):214-7. PubMed ID: 2346126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma.
    Richard MA; Grob JJ; Zarrour H; Bassères N; Bizzari JP; Gérard B; Bonerandi JJ
    Melanoma Res; 1998 Apr; 8(2):170-4. PubMed ID: 9610872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose cisplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma.
    Buzaid AC; Murren JR; Durivage HJ
    Cancer; 1991 Sep; 68(6):1238-41. PubMed ID: 1873775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.